The FDA has twice opted not to approve Replimune’s oncolytic immunotherapy RP1 for melanoma despite breakthrough therapy designation and fast-track expectations, according to the account provided. RP1 is an engineered herpesvirus injected into tumors to induce cancer-cell lysis and downstream immune activation.